Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults with Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes (ELICIT)
Details
Age
Adult
Type of Study
Treatment
Scope
National
Locations
Outpatient CTRC
Principal Investigator
Thomas Campbell, MD
Study ID
Protocol Number: 21-4059
More information available at ClinicalTrials.gov: NCT04840199
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers